[Edaily Starin Gim Ga Yeong Reporter] Juyeon, a member of the group THE BOYZ, has signed an exclusive contract with Ace Factory.
On the 24th, Ace Factory stated, “We are delighted to have formed this precious partnership with Joo-yeon, an artist who possesses exceptional stage presence and profound emotional expression. We will provide our full support so that Joo-yeon’s boundless potential and unique charm can flourish in his new career as an actor.” They added, “We respect the musical achievements of THE BOYZ, which serve as Joo-yeon’s roots and artistic identity, and we will do our best to ensure that his continued group activities—built on the trust established with fans—and his leap into acting create positive synergy.” Joo-yeon gained immense popularity after debuting with the group THE BOYZ in 2017. THE BOYZ, the group to which Joo-yeon belongs, has grown through active domestic and international activities. Last year, they successfully concluded their fourth world tour, “THE BOYZ THE BLaze World Tour,” which included six cities in Asia and five in the Americas, showcasing their spectacular capabilities as a global K-pop group. Joo-yeon has demonstrated a wide artistic spectrum, proving his exceptional star power and popularity not only through his intense stage presence but also in various fields such as fashion and variety shows. Ace Factory, which has signed an exclusive contract with Ju-yeon, is a comprehensive entertainment agency engaged in drama production and artist management. Its roster includes actors Lee Jong-suk, Lee Jun-hyuk, Yoo Jae-myung, Yeom Hye-ran, Yoon Se-ah, Lee Kyu-hyung, Jang Seung-jo, Choi Dae-hoon, and many others. Previously, THE BOYZ member Eric signed an exclusive contract with Grid Entertainment, and Young-hoon signed an exclusive contract with Namoo Actors.
“Donghaeng,” a labor union composed primarily of employees from SamsungElectronics’ Device Experience (DX) Division, is holding a rally in front of Jay Y. Lee’s residence to demand the elimination of …
SK BIOPHARMACEUTICALS(326030)is attributing significance beyond that of a mere follow-up pipeline to Opakalim (BHV-7000), a new epilepsy drug candidate it acquired from the U.S.-based Biohaven. It is …
South Korea’s pharmaceutical and biotech sector experienced significant volatility on August 13, driven by growth themes in obesity/medical aesthetics, hair loss, and immuno-oncology. #GCWellbeing sur…